Not long after the FDA wrapped its preliminary investigation of GLP-1 receptor agonists and suicidal thoughts or actions, the ...

However the trial didn't demonstrate any extra 'synergistic' benefits in combining the drugs, which other GLP-1 plus SGLT2 inhibitor trials have shown. A trial of AstraZeneca's GLP-1 Bydureon ...

The analysis included five trials for DPP-4 inhibitors, eight for GLP-1 RAs, and 14 for SGLT2 inhibitors. The oldest trial was in 2013 and the most recent in 2023. The studies investigated ...

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower rates of hospital readmission, wound re-opening and hematoma after surgery ...

Of patients who met the high-risk criteria, 55% were not on American Diabetes Association (ADA) guideline-directed medication therapy with an SGLT-2 inhibitor or GLP-1 agonist. In only 34% of ...

The quest for effective weight loss solutions has never been more urgent, with millions of people worldwide struggling to ...

This enhancement is linked to increased expression levels of GLP-1 receptors and intracellular ... shown to be complementary to metformin and SGLT2 inhibitors, two very commonly used agents ...

A recent study published in JAMA Network Open has revealed an unexpected connection between GLP-1 receptor agonist medications, commonly used for weight management, and a reduction in alcohol ...